Regulators Call for More Harmonization On Ultra-Rare ATMPs
Executive Summary
Early discussions between companies and multiple regulators could drive greater alignment among jurisdictions.
You may also be interested in...
Do Fast Track Regulatory Pathways Mean Quicker Reimbursement For Gene Therapies?
The norms on securing market access are being rewritten for cell and gene therapies.
Three EU Countries Strike Landmark Joint Zolgensma Pricing Deal
BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.
Confronting The Challenges Of Marketing Cell And Gene Therapies
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.